What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
David P. Dearnaley focuses on Prostate cancer, Internal medicine, Surgery, Oncology and Radiation therapy.
His Prostate cancer research entails a greater understanding of Cancer.
His biological study spans a wide range of topics, including Endocrinology and Gynecology.
David P. Dearnaley usually deals with Surgery and limits it to topics linked to Urology and Chemotherapy.
His work carried out in the field of Oncology brings together such families of science as Odds ratio and Hormonal therapy.
His Radiation therapy research includes elements of Androgen suppression, Rectum and Nuclear medicine.
His most cited work include:
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial (949 citations)
- Multiple newly identified loci associated with prostate cancer susceptibility. (754 citations)
- Multiple newly identified loci associated with prostate cancer susceptibility. (754 citations)
What are the main themes of his work throughout his whole career to date?
David P. Dearnaley spends much of his time researching Prostate cancer, Internal medicine, Oncology, Radiation therapy and Surgery.
David P. Dearnaley combines subjects such as Prostate, Randomized controlled trial and Urology with his study of Prostate cancer.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Gynecology.
His Oncology study incorporates themes from Hormone therapy, Disease and Abiraterone acetate.
The various areas that David P. Dearnaley examines in his Radiation therapy study include Toxicity, Rectum and Nuclear medicine.
Proportional hazards model is closely connected to Hazard ratio in his research, which is encompassed under the umbrella topic of Surgery.
He most often published in these fields:
- Prostate cancer (62.35%)
- Internal medicine (51.64%)
- Oncology (38.99%)
What were the highlights of his more recent work (between 2015-2021)?
- Prostate cancer (62.35%)
- Internal medicine (51.64%)
- Oncology (38.99%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Prostate cancer, Internal medicine, Oncology, Radiation therapy and Prostate.
His research investigates the connection with Prostate cancer and areas like Hazard ratio which intersect with concerns in Prospective cohort study.
His Oncology research incorporates elements of Locally advanced, Abiraterone acetate, Abiraterone and Hormone sensitive prostate cancer.
His study on Radiation therapy is covered under Surgery.
His study in Surgery is interdisciplinary in nature, drawing from both Bladder cancer and Hypofractionated Radiotherapy.
His research in Clinical endpoint tackles topics such as Urology which are related to areas like External beam radiotherapy.
Between 2015 and 2021, his most popular works were:
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial (949 citations)
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy (722 citations)
- Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial (480 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
His primary areas of investigation include Prostate cancer, Internal medicine, Oncology, Radiation therapy and Hazard ratio.
Specifically, his work in Prostate cancer is concerned with the study of Prostate-specific antigen.
David P. Dearnaley interconnects Androgen deprivation therapy, Abiraterone acetate, Single-nucleotide polymorphism and Prospective cohort study in the investigation of issues within Oncology.
His Radiation therapy study contributes to a more complete understanding of Surgery.
His research investigates the connection between Surgery and topics such as Bladder cancer that intersect with problems in Image-Guided Adaptive Radiation Therapy, Radiography and Chemotherapy.
The Prostate study combines topics in areas such as Localised disease and Magnetic resonance imaging, Radiology.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
